Hubei Biocause Heilen Pharmaceutical Co., Ltd.
SZSE:301211.SZ
21.24 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 445.864 | 663.026 | 514.912 | 540.623 | 592.924 | 660.019 | 517.144 | 366.409 |
| Cost of Revenue
| 317.274 | 396.675 | 366.218 | 357.12 | 298.54 | 319.227 | 295.626 | 265.676 |
| Gross Profit
| 128.591 | 266.351 | 148.694 | 183.502 | 294.385 | 340.792 | 221.518 | 100.733 |
| Gross Profit Ratio
| 0.288 | 0.402 | 0.289 | 0.339 | 0.496 | 0.516 | 0.428 | 0.275 |
| Reseach & Development Expenses
| 31.555 | 52.775 | 19.845 | 18.281 | 22.976 | 24.995 | 20.87 | 17.705 |
| General & Administrative Expenses
| 12.467 | 13.351 | 8.866 | 9.559 | -13.05 | -33.985 | -47.212 | 8.653 |
| Selling & Marketing Expenses
| 17.48 | 18.643 | 14.906 | 11.972 | 14.209 | 51.415 | 48.303 | 23.884 |
| SG&A
| 29.947 | 31.995 | 23.772 | 21.531 | 1.158 | 17.43 | 1.091 | 32.536 |
| Other Expenses
| -35.175 | -23.752 | -1.284 | -0.102 | 28.168 | 2.736 | 17.814 | -0.032 |
| Operating Expenses
| 27.709 | 60.138 | 66.954 | 52.235 | 91.105 | 127.068 | 107.919 | 64.3 |
| Operating Income
| 100.882 | 205.334 | 148.726 | 139.287 | 198.96 | 218.102 | 107.447 | 26.957 |
| Operating Income Ratio
| 0.226 | 0.31 | 0.289 | 0.258 | 0.336 | 0.33 | 0.208 | 0.074 |
| Total Other Income Expenses Net
| -0.463 | -2.518 | -1.284 | -0.102 | -0.328 | -1.102 | -0.826 | -0.032 |
| Income Before Tax
| 100.419 | 202.816 | 147.442 | 139.185 | 198.632 | 217 | 106.62 | 26.925 |
| Income Before Tax Ratio
| 0.225 | 0.306 | 0.286 | 0.257 | 0.335 | 0.329 | 0.206 | 0.073 |
| Income Tax Expense
| 8.872 | 26.7 | 21.718 | 17.535 | 30.559 | 32.376 | 15.143 | 3.153 |
| Net Income
| 91.547 | 176.116 | 125.793 | 121.649 | 168.073 | 100.289 | 47.735 | 10.268 |
| Net Income Ratio
| 0.205 | 0.266 | 0.244 | 0.225 | 0.283 | 0.152 | 0.092 | 0.028 |
| EPS
| 0.32 | 0.61 | 0.44 | 0.42 | 0.58 | 0.35 | 0.22 | 0.05 |
| EPS Diluted
| 0.32 | 0.61 | 0.44 | 0.42 | 0.58 | 0.35 | 0.22 | 0.05 |
| EBITDA
| 126.164 | 225.152 | 169.774 | 158.925 | 219.334 | 236.828 | 129.611 | 45.464 |
| EBITDA Ratio
| 0.283 | 0.34 | 0.33 | 0.294 | 0.37 | 0.359 | 0.251 | 0.124 |